Details - Pidar

Dataset ID: 5

Back to List

Study Design Background	Assessment of the uptake of a novel CXCR-4 directed radiolabelled peptide in naive and tumor bearing animals.
Study Description	CXCR4
Study Type	preclinical
Study Subtype	in vitro and in vivo

Paper Linked	yes
Paper Title	D-Peptide-Based Probe for CXCR4-Targeted Molecular Imaging and Radionuclide Therapy
Paper Authors	Kaat Luyten(1), Tom Van Loy(256), Christopher Cawthorne(3), Christophe M. Deroose(3), Dominique Schols(256), Guy Bormans(1) and Frederik Cleeren(1)
Affiliation	Laboratory for Radiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven; Laboratory of Virology and Chemotherapy, Department of Microbiology, Immunology and Transplantation, KU Leuven; Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven; 3000 Leuven, Belgium
Paper Journal	Pharmaceutics
Paper Year	2022
Paper Doi	https://doi.org/10.3390/pharmaceutics13101619
Open Access	yes
Updated Year	2022

Institution	KU Leuven
Pi	Frederik Cleeren
Country Of Institution	Belgium
Imaging Facility	Molecular Small Animal Imaging Centre (MoSAIC), KU Leuven
Euro Bio Imaging Node	Flanders BioImaging (Candidate EuBI node)
Country Of Imaging Facility	Belgium

Number Of Groups	2
Types Of Groups	naive animals -/+ CXCR4 blocking drug
Overall Sample Size	9
Disease Model	healthy animals
Organ Or Tissue	liver, kidneys
Sample Size For Each Group	5 animals for tracer uptake, 4 animals for tracer uptake + blocking compound
Power Calculation	The number of animals included in the study was based on previous reports where an approximately 70% difference was seen between naïve and blocked animals in CXCR4 expressing organs [https://jnm.snmjournals.org/content/61/1/123]. Detection of such difference therefore required 3 animals per group (power = 0.95 and a = 0.05) assuming a 20% standard deviation within the groups.
Inclusion Criteria	none
Exclusion Criteria	none
Randomization	Yes. All animals included in the study were randomly selected among the in-house bred mice of the correct age.
Blinding	no
Procedures To Keep Treatments Blind	n/a
Procedures To Keep Experimenter Blind	n/a
Outcome Measures	Time activity curves showing uptake in kidneys and liver over the 1hr scan period -/+ blocking agent
Statistical Methods	one tail t-test for independent groups assuming unequal variances
Species	Mice
Strain	NMRI
Immune Status	immune competent
Sex	Female
Age	5 weeks on arrival
Age At Start Experiment	30 weeks
Age At Scanning Experiment S	30-32 weeks
Weight At Start Experiment	35-45g
Weight At End Experiment	35-45g
Source Of Animals	Envigo (Netherlands)

Pharmacological Procedures Intervention And Control	yes
Pharmacological Drug	AMD3100
Formulation	PBS
Drug Dose	5mg/kg
Site Route Of Administration	iv
Frequency Of Administration	once, at the start of scanning
Vehicle Or Carrier Solution Formulation	PBS
Blood Sampling	no
Surgical Procedures Including Sham Surgery	no
Pathogen Infection Intervention And Control	no pathogens used
Analgesic Plan To Relieve Pain Suffering And Distress	no
Anesthesia Type	gas
Duration	75-90
Anesthesia Drugs	isoflurane
Anesthesia Dose	1-2%
Monitoring Regime	respiratory and temperature monitoring whilst scanning, visual surveillance during preparation and recovery
Euthanasia	yes
Method	cervical dislocation
Histology	no
Frequency Of Imaging	Single scan
Timing Of Imaging	Animals scanned in accordance with radiotracer production schedule
Overall Scan Length	60 minute PET + CT
Contrast Agent Or Radio Isotope Or Challenge With Gas Molecule	yes
Contrast Agent Commercial Drug	none, Pentixafor
Contrast Agent Chemical Drug	[18F]AlF-NOTA-DV1-k-(DV3),
Contrast Agent Dose	1.5-3.0MBq
Injection Volume	0.15-0.225ml
Injection Time	8-10 seconds
Vehicle	Saline
Route Of Administration	intravenous
Cell Lines	None
Housing Room	not SPF
Dietary Intervention	none
Respiration Rate	only during scanning
Body Tempurature Etc	only during scanning
Food Intake Measured	no

Instrument Vendor	Molecubes
Instrument Type	β-cube, X-cube
Instrument Specifics	PET: Axial FOV 130 mm, Transaxial FOV 72 mm, Resolution 850 µm, Peak Sensitivity > 12 %, Energy Resolution 12,6 %, LYSO cont./SiPM CT: cone-shaped X-ray beam and detector, tungsten anode source with focal spot size of 33µm.
Image Acquisition Parameters	PET: 60 minute dynamic acquisition, Energy window 434-588 KeV. CT: 50 kVp, 480 exposures, 85 ms/projection, 100 µA tube current, rotation time 60 s, 0.8mm Al beam filtration.
Correction	PET: Decay, Attenuation, Scatter, Dead time, Randoms corrected. Non-uniform radial sampling corrected, sensitivity calibrated against dose calibrator, detectors normalized.
Raw Data	no
Qa Qc	regular QA/QC carried out on scanners, which are under service contract

Image Type	Processed images (reconstructed PET and CT data)
Image Scale	HU for CT, SUV for PET
Format Compression	DICOM
Dimensions	3D
Overall Number Of Images	3 x PET, 3 x CT for original images, 9 individual images
Field Of View	70x70x124.8 (CT); 76.8x76.8x 153.6 (PET) for multiple animal image; individual cropped images vary
Dimension Extents	350x350x624 (CT); 192x192x384 (PET) for multiple animal image; individual cropped images vary
Size Description	70x70x124.8 (CT); 76.8x76.8x 153.6 (PET) for multiple animal image; individual cropped images vary
Pixel Voxel Size Description	0.2mm (CT), 0.4mm (PET)
Image Processing Methods	Images reconstructed as below.
Image Reconstruction Algorithm	OSEM (PET), 30 iterations. Iterative (CT)
Quality Control	n/a
Image Smoothing Or Filtering Algorithm	n/a
Image Registration Algorithm	n/a
Qc Info	QC: high (injections all successful as evidenced by dynamic images)
Corrections	Corrections listed above
Spatial And Temporal Alignment	PET and CT images aligned using rigid registration in PMOD 4.0.
Fiducials Used	None
Coregistered Images	Dataset includes coregistered datasets for individual animals
Transformation Matrix Other Info	Transformation matrix not saved, but original multiple-animal images available
Related Images And Relationship	PET and CT images aligned using rigid registration in PMOD 4.0.

Analysis Result Type	Numerical
Data Used For Analysis	Time activity curves generated by manual delineation of kidneys and a sphere centred on the liver, scaled to SUV
Analysis Method And Details	Manual delineation of organs/placement of spherical ROIs in PMOD v 4.0.
Status	complete

Back to List